McKesson Corporation ( (MCK) ) has released its Q2 earnings. Here is a breakdown of the information McKesson Corporation presented to its ...
Analyst Charles Rhyee from TD Cowen maintained a Buy rating on McKesson (MCK – Research Report) and decreased the price target to $651.00 ...
Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that ...
Highlights:,Baird upgraded McKesson Corporation’s stock from Neutral to Outperform, raising its price target to $688 from $531.,McKesson's strong performance in the U.S. Pharmaceutical Distribution ...
Fletcher-Hill sends the case to the jury for consideration. Baltimore alleges that the companies, McKesson and AmerisourceBergen, flooded the city with hundreds of millions of addictive pain pills ...
McKesson Corp (MCK) reports a 21% revenue increase and raises fiscal 2025 EPS guidance amid strategic expansions and challenges.
Operator Ladies and gentlemen, welcome to McKesson's second quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn ...
McKesson (MCK) delivered earnings and revenue surprises of 2.61% and 4.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Following Donald Trump's election night victory, many publicly traded businesses in Dallas-Fort Worth saw a rise in stock ...
McKesson (MCK) reported $93.65 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 21.3%. EPS of $7.07 for the same period compares to $6.23 a year ago.
Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S.
Intellinetics, Inc. , a digital transformation solutions provider, today announced that it will report its financial results for the third quarter of 2024, the period ended September 30, 2024, on ...